Zobrazeno 1 - 10
of 441
pro vyhledávání: ''
Publikováno v:
The American Journal of Medicine. 133:1322-1327
Background Statins are the first-line therapy for reducing low-density lipoprotein cholesterol (LDL-C). However, there are secondary prevention patients who are either intolerant to maximal statin therapy or do not get adequate effects from a high-in
Publikováno v:
The American Journal of Medicine. 133:347-351
Background Ivabradine, a heart rate-slowing drug used to treat heart failure and (in Europe) angina, had varying impacts upon cardiovascular events in its 3 large outcome trials. Food and Drug Administration (FDA) analyses may explain the reasons for
Publikováno v:
The American Journal of Medicine. 131:134-140
Lifestyle modification is the cornerstone of preventing atherosclerotic cardiovascular disease. When this is not sufficient in reducing risk, statin therapy is first line. Heart Outcomes Prevention Evaluation (HOPE-3) was a randomized controlled tria
Autor:
Sherry M Bumpus, George Cholack, Rachel Krallman, Daniel G. Montgomery, Melvyn Rubenfire, Eva Kline-Rogers, Thomas Cascino, Joshua Garfein, Geoffrey D. Barnes
Publikováno v:
Am J Med
Background Heart failure with reduced ejection fraction and atrial fibrillation commonly coexist. Most calcium channel blockers are not recommended in heart failure with reduced ejection fraction, but their use has been seldom evaluated. For patients
Publikováno v:
The American Journal of Medicine. 129:1299-1306
Vertebral fracture is the most common type of osteoporotic fracture. While thiazide diuretics, which are commonly prescribed for the treatment of hypertension, decrease calciuria, they may also induce hyponatremia, which has been associated with incr
Autor:
David A. DeMicco, Sripal Bangalore, John J.P. Kastelein, Rachel Laskey, Rana Fayyad, David D. Waters, Pierre Amarenco
Publikováno v:
American journal of medicine, 129(4), 384-391. Elsevier Inc.
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol recommends moderate- to high-intensity statins for patients with atherosclerotic cardiovascular disease but departs from th
Autor:
Vanessa Roldán, Josefa Gálvez, Francisco Marín, Gregory Y.H. Lip, Mariano Valdés, Vicente Vicente, Shirley Cancio
Publikováno v:
The American Journal of Medicine. 128:1237-1243
International guidelines recommend that an average individual time in therapeutic range should be65% to 70% for optimal efficacy and safety outcomes while taking a vitamin K antagonist. The Sex, Age (60 years); Medical history (at least 2 of the foll
Autor:
Helen Newton, Peter Scalia, Natalie B.V. Riblet, Saiganesh Ravikumar, Martha DesBiens, Andrew Glick, Okechukwu Erinne
Publikováno v:
The American Journal of Medicine. 133:452-462.e4
Background True allergy to penicillin is rare, despite the high frequency with which it is reported. While most patients reporting penicillin allergy are not prone to anaphylaxis, it is not currently known what percentage of these patients will toler
Publikováno v:
The American Journal of Medicine. 133:95-99.e6
Background The relationship between cholesterol levels and stroke has been much less clear than the relationship between cholesterol levels and coronary heart disease. This is likely mostly due to the inadequate power of older studies and the low int
Publikováno v:
The American Journal of Medicine. 129:1331-1333
Background Widespread penicillin usage rapidly resulted in the emergence of penicillin resistance in Staphylococcus aureus . However, new data suggest that penicillin susceptibility may be in a period of renaissance. The objective of our study was to